Drugs / TAS1440
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04282668 | Mar 2020 → Feb 2024 | acute myeloid leukemia | Taiho Oncology, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAS1440 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04282668 ↗ |
| Route | Oral | “Route of Administration: Oral” NCT04282668 ↗ |